US6207646B1
(en)
|
1994-07-15 |
2001-03-27 |
University Of Iowa Research Foundation |
Immunostimulatory nucleic acid molecules
|
US6406705B1
(en)
|
1997-03-10 |
2002-06-18 |
University Of Iowa Research Foundation |
Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
|
US20020147143A1
(en)
|
1998-03-18 |
2002-10-10 |
Corixa Corporation |
Compositions and methods for the therapy and diagnosis of lung cancer
|
US6908757B1
(en)
|
1998-03-26 |
2005-06-21 |
The Procter & Gamble Company |
Serine protease variants having amino acid deletions and substitutions
|
WO1999061056A2
(en)
|
1998-05-22 |
1999-12-02 |
Loeb Health Research Institute At The Ottawa Hospital |
Methods and products for inducing mucosal immunity
|
ES2485940T3
(es)
|
1998-05-29 |
2014-08-14 |
Novartis Vaccines And Diagnostics, Inc. |
Combinación de vacunas contra Meningitis B/C
|
US20030235557A1
(en)
|
1998-09-30 |
2003-12-25 |
Corixa Corporation |
Compositions and methods for WT1 specific immunotherapy
|
DE60015084T2
(de)
*
|
1999-02-26 |
2006-02-16 |
Chiron S.R.L. |
Verbesserung der bakterizidaktivität von neisseria antigenen mit cg enthaltende oligonukleotiden
|
DE60032120T2
(de)
|
1999-03-19 |
2007-09-20 |
Glaxosmithkline Biologicals S.A. |
Impstoff gegen Streptococcus pneumoniae
|
YU72901A
(sh)
|
1999-04-02 |
2004-07-15 |
Corixa Corporation |
Preparati za primenu u terapiji i dijagnozi raka pluća
|
KR100922031B1
(ko)
|
1999-04-19 |
2009-10-19 |
글락소스미스클라인 바이오로지칼즈 에스.에이. |
백신
|
US6558670B1
(en)
|
1999-04-19 |
2003-05-06 |
Smithkline Beechman Biologicals S.A. |
Vaccine adjuvants
|
WO2000062802A2
(en)
*
|
1999-04-20 |
2000-10-26 |
Smithkline Beecham Biologicals Sa |
Vaccine comprising rsv antigen and cpg oligonucleotide
|
DE60023300T2
(de)
*
|
1999-06-29 |
2006-07-06 |
Glaxosmithkline Biologicals S.A. |
Verwendung von cpg als adjuvans für hivimpstoff
|
SK782002A3
(en)
*
|
1999-07-21 |
2003-08-05 |
Lexigen Pharm Corp |
FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
|
KR20020021397A
(ko)
|
1999-07-22 |
2002-03-20 |
데이비드 엠 모이어 |
규정된 에피토프 영역에 아미노산 결실 및 치환을 갖는서브틸리신 프로테아제 변이체
|
CN1399677A
(zh)
|
1999-07-22 |
2003-02-26 |
宝洁公司 |
在确定表位区有氨基酸取代的枯草杆菌蛋白酶变体
|
CN1377406A
(zh)
|
1999-07-22 |
2002-10-30 |
宝洁公司 |
具有空间保护的切割位点的蛋白酶缀合物
|
US6946128B1
(en)
|
1999-07-22 |
2005-09-20 |
The Procter & Gamble Company |
Protease conjugates having sterically protected epitope regions
|
EP1204425B1
(en)
|
1999-08-19 |
2009-01-07 |
Dynavax Technologies Corporation |
Methods of modulating an immune response using immunostimulatory sequences and compositions for use therein
|
GB9925559D0
(en)
*
|
1999-10-28 |
1999-12-29 |
Smithkline Beecham Biolog |
Novel method
|
US7223398B1
(en)
|
1999-11-15 |
2007-05-29 |
Dynavax Technologies Corporation |
Immunomodulatory compositions containing an immunostimulatory sequence linked to antigen and methods of use thereof
|
GB9928196D0
(en)
|
1999-11-29 |
2000-01-26 |
Chiron Spa |
Combinations of B, C and other antigens
|
DK1650221T3
(da)
|
2000-02-23 |
2012-09-03 |
Glaxosmithkline Biolog Sa |
Nye forbindelser
|
US20040002068A1
(en)
|
2000-03-01 |
2004-01-01 |
Corixa Corporation |
Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
|
US7157437B2
(en)
|
2000-03-10 |
2007-01-02 |
Dynavax Technologies Corporation |
Methods of ameliorating symptoms of herpes infection using immunomodulatory polynucleotide sequences
|
US20010046967A1
(en)
|
2000-03-10 |
2001-11-29 |
Gary Van Nest |
Methods of preventing and treating respiratory viral infection using immunomodulatory polynucleotide
|
US20020098199A1
(en)
|
2000-03-10 |
2002-07-25 |
Gary Van Nest |
Methods of suppressing hepatitis virus infection using immunomodulatory polynucleotide sequences
|
US20030129251A1
(en)
|
2000-03-10 |
2003-07-10 |
Gary Van Nest |
Biodegradable immunomodulatory formulations and methods for use thereof
|
US7129222B2
(en)
|
2000-03-10 |
2006-10-31 |
Dynavax Technologies Corporation |
Immunomodulatory formulations and methods for use thereof
|
CA2407114A1
(en)
|
2000-04-21 |
2001-11-01 |
Corixa Corporation |
Compounds and methods for treatment and diagnosis of chlamydial infection
|
AUPQ761200A0
(en)
*
|
2000-05-19 |
2000-06-15 |
Hunter Immunology Limited |
Compositions and methods for treatment of mucosal infections
|
IL152935A0
(en)
|
2000-05-19 |
2003-06-24 |
Corixa Corp |
Prophylactic and therapeutic treatment of infectious and other diseases with mono and dissaccharide-based compounds
|
ES2374620T3
(es)
|
2000-06-20 |
2012-02-20 |
Corixa Corporation |
Antígeno mtb32a de mycobacterium tuberculosis con el sitio activo inactivado y proteínas de fusión de los mismos.
|
WO2002000242A2
(en)
|
2000-06-26 |
2002-01-03 |
Stressgen Biotechnologies Corporation |
Human papilloma virus treatment
|
WO2002000174A2
(en)
|
2000-06-28 |
2002-01-03 |
Corixa Corporation |
Compositions and methods for the therapy and diagnosis of lung cancer
|
CA2430691A1
(en)
|
2000-12-27 |
2002-07-04 |
Dynavax Technologies Corporation |
Immunomodulatory polynucleotides and methods of using the same
|
EP1515982A4
(en)
|
2001-05-09 |
2005-10-26 |
Corixa Corp |
METHODS AND COMPOSITIONS FOR THE THERAPY AND DIAGNOSIS OF PROSTATE CANCER
|
ES2421532T3
(es)
|
2001-06-21 |
2013-09-03 |
Dynavax Tech Corp |
Compuestos inmunomoduladores quiméricos y métodos de uso de los mismos
|
WO2003014316A2
(en)
|
2001-08-07 |
2003-02-20 |
Dynavax Technologies Corporation |
Immunomodulatory compositions, formulations, and methods for use thereof
|
CA2461056A1
(en)
|
2001-09-20 |
2003-03-27 |
Glaxo Group Limited |
Hiv-gag codon-optimised dna vaccines
|
ES2405405T3
(es)
|
2001-12-17 |
2013-05-31 |
Corixa Corporation |
Composiciones y procedimientos para la terapia y el diagnóstico de enfermedad inflamatoria del intestino
|
CA2388049A1
(en)
|
2002-05-30 |
2003-11-30 |
Immunotech S.A. |
Immunostimulatory oligonucleotides and uses thereof
|
JP2005533855A
(ja)
|
2002-07-24 |
2005-11-10 |
インターツェル・アクチェンゲゼルシャフト |
病原性ウイルスからの別のリーディングフレームによりコードされる抗原
|
CA2484339A1
(en)
|
2002-09-13 |
2004-03-25 |
Intercell Ag |
Method for isolating hepatitis c virus peptides
|
KR20050089799A
(ko)
|
2002-10-29 |
2005-09-08 |
콜리 파마슈티칼 그룹, 리미티드 |
C형 간염 바이러스 감염의 치료에 있어 CpG올리고뉴클레오티드의 용도
|
WO2004053104A2
(en)
|
2002-12-11 |
2004-06-24 |
Coley Pharmaceutical Group, Inc. |
5’ cpg nucleic acids and methods of use
|
KR100525321B1
(ko)
*
|
2002-12-13 |
2005-11-02 |
안웅식 |
파필로마바이러스 항원 단백질 및CpG-올리고데옥시뉴클레오타이드를 포함하는파필로마바이러스 유발 질환의 예방 또는 치료용 약제학적조성물
|
PT1992635E
(pt)
|
2002-12-23 |
2012-03-20 |
Dynavax Tech Corp |
Oligonucleótidos de sequência imunoestimuladora e métodos de utilização dos mesmos
|
US8158768B2
(en)
|
2002-12-23 |
2012-04-17 |
Dynavax Technologies Corporation |
Immunostimulatory sequence oligonucleotides and methods of using the same
|
KR101110889B1
(ko)
|
2003-01-06 |
2012-02-20 |
코릭사 코포레이션 |
특정의 아미노알킬 글루코사미나이드 포스페이트 화합물 및그들의 용도
|
US7960522B2
(en)
|
2003-01-06 |
2011-06-14 |
Corixa Corporation |
Certain aminoalkyl glucosaminide phosphate compounds and their use
|
JP2006521321A
(ja)
*
|
2003-03-24 |
2006-09-21 |
インターツェル・アクチェンゲゼルシャフト |
免疫応答を促進するためのミョウバンおよびTh1免疫応答誘起アジュバントの使用
|
ATE485056T1
(de)
|
2003-03-24 |
2010-11-15 |
Intercell Ag |
Verbesserte impfstoffe
|
WO2004100965A1
(ja)
*
|
2003-05-15 |
2004-11-25 |
Japan Science And Technology Agency |
免疫刺激剤
|
US20090028874A1
(en)
*
|
2003-12-24 |
2009-01-29 |
Leiden University Medical Center |
Synthetic Protein as Tumor-Specific Vaccine
|
CA2837748C
(en)
|
2004-05-25 |
2016-03-08 |
Oregon Health And Science University |
Siv and hiv vaccination using rhcmv-and hcmv-based vaccine vectors
|
EP2808384B1
(en)
|
2004-10-08 |
2017-12-06 |
The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services |
Modulation of replicative fitness by using less frequently used synonymous codons
|
EP2392348A3
(en)
|
2005-03-31 |
2012-01-18 |
GlaxoSmithKline Biologicals S.A. |
Vaccines against chlamydial infection
|
EP1877426B1
(en)
|
2005-04-29 |
2012-02-01 |
GlaxoSmithKline Biologicals SA |
Method for preventing or treating m tuberculosis infection
|
EP1981905B1
(en)
|
2006-01-16 |
2016-08-31 |
THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES |
Chlamydia vaccine
|
CN101421306B
(zh)
*
|
2006-04-19 |
2013-09-18 |
浦项工科大学校产学协力团 |
用于治疗和预防子宫颈癌的包含hpv多肽和免疫增强肽的组合物
|
AU2007345768B2
(en)
*
|
2006-07-27 |
2013-08-01 |
Ligocyte Pharmaceuticals, Inc. |
Chimeric influenza virus-like particles
|
EP2044224A4
(en)
*
|
2006-07-27 |
2011-04-13 |
Ligocyte Pharmaceuticals Inc |
CHIMERIC VIRUS TYPE PARTICLES
|
CN104815324A
(zh)
|
2007-04-04 |
2015-08-05 |
传染性疾病研究院 |
包含结核分枝杆菌多肽及其融合的免疫原性组合物
|
US8518903B2
(en)
|
2007-04-19 |
2013-08-27 |
University of Pittsburgh—of the Commonwealth System of Higher Education |
Use of toll-like receptor-9 agonists
|
TW200908994A
(en)
|
2007-04-20 |
2009-03-01 |
Glaxosmithkline Biolog Sa |
Vaccine
|
EA201300102A1
(ru)
|
2007-05-24 |
2014-02-28 |
Глаксосмитклайн Байолоджикалс С.А. |
Лиофилизированная антигенная композиция
|
JP2008308474A
(ja)
*
|
2007-06-18 |
2008-12-25 |
Nitto Denko Corp |
抗原ペプチド製剤の調製方法
|
EP2170384B1
(en)
|
2007-07-02 |
2016-04-13 |
Etubics Corporation |
Methods and compositions for producing an adenovirus vector for use with multiple vaccinations
|
WO2009061996A2
(en)
|
2007-11-07 |
2009-05-14 |
Celldex Therapeutics Inc. |
Antibodies that bind human dendritic and epithelial cell 205 (dec-205)
|
BRPI0821532A2
(pt)
|
2007-12-24 |
2015-06-16 |
Id Biomedical Corp Quebec |
Antígenos de rsv recombinantes
|
WO2010063865A1
(es)
|
2008-12-03 |
2010-06-10 |
Proyecto De Biomedicina Cima, S.L. |
Uso de modulinas solubles en fenol para el desarrollo de vacunas
|
CA2653478A1
(en)
*
|
2009-01-23 |
2010-07-23 |
Gregg Martin |
Automated wash system for industrial vehicles
|
US20120052088A1
(en)
*
|
2009-04-30 |
2012-03-01 |
Coley Pharmaceutical Group, Inc. |
Pneumococcal vaccine and uses thereof
|
MX2012000036A
(es)
|
2009-06-24 |
2012-02-28 |
Glaxosmithkline Biolog Sa |
Vacuna.
|
HUE028085T2
(en)
|
2009-06-24 |
2016-11-28 |
Glaxosmithkline Biologicals Sa |
Recombinant RSV antigens
|
HRP20220756T1
(hr)
|
2009-07-15 |
2022-09-02 |
Glaxosmithkline Biologicals S.A. |
Proteinski pripravci rsv f i postupci za izradu istih
|
GB0919117D0
(en)
|
2009-10-30 |
2009-12-16 |
Glaxosmithkline Biolog Sa |
Process
|
JP5917402B2
(ja)
|
2009-11-03 |
2016-05-11 |
タケダ ヴァクシーンズ, インコーポレイテッド |
キメラRSV−Fポリペプチド、およびレンチウイルスGagまたはアルファレトロウイルスGagに基づくVLP
|
WO2011101332A1
(en)
|
2010-02-16 |
2011-08-25 |
Proyecto De Biomedicina Cima, S.L. |
Compositions based on the fibronectin extracellular domain a for the treatment of melanoma
|
KR101958753B1
(ko)
|
2010-04-13 |
2019-03-15 |
셀덱스 쎄라퓨틱스, 인크. |
인간 cd27에 결합하는 항체 및 이의 용도
|
US9072760B2
(en)
|
2010-09-24 |
2015-07-07 |
University of Pittsburgh—of the Commonwealth System of Higher Education |
TLR4 inhibitors for the treatment of human infectious and inflammatory disorders
|
US10668092B2
(en)
|
2010-09-24 |
2020-06-02 |
The John Hopkins University |
Compositions and methods for treatment of inflammatory disorders
|
WO2012057904A1
(en)
|
2010-10-27 |
2012-05-03 |
Infectious Disease Research Institute |
Mycobacterium tuberculosis antigens and combinations thereof having high seroreactivity
|
EA201390676A1
(ru)
|
2010-11-08 |
2013-11-29 |
Инфекшес Дизиз Рисерч Инститьют |
Вакцины, содержащие полипептиды неспецифической нуклеозидгидролазы и стерол 24-c-метилтрансферазы (smt), для лечения и диагностики лейшманиоза
|
TWI507413B
(zh)
*
|
2010-11-15 |
2015-11-11 |
Nat Health Research Institutes |
脂質化多抗原表位疫苗
|
EA027920B1
(ru)
|
2010-12-14 |
2017-09-29 |
Глаксосмитклайн Байолоджикалс С.А. |
Композиция микобактериальных антигенов
|
WO2012088425A2
(en)
|
2010-12-22 |
2012-06-28 |
University Of Pittsburgh - Of The Commonwealth System Of Higher Education |
Gap junction-enhancing agents for treatment of necrotizing enterocolitis and inflammatory bowel disease
|
EP2505640A1
(en)
|
2011-03-29 |
2012-10-03 |
Neo Virnatech, S.L. |
Vaccine compositions for birnavirus-borne diseases
|
GB201106357D0
(en)
|
2011-04-14 |
2011-06-01 |
Pessi Antonello |
Composition and uses thereof
|
MX2013013627A
(es)
|
2011-06-21 |
2014-04-25 |
Oncofactor Corp |
Composiciones y metodos para la terapia y diagnostico de cancer.
|
CN102343103B
(zh)
*
|
2011-07-26 |
2016-04-27 |
马丁 |
人乳头状瘤病毒16型三肽疫苗的筛选和验证及持续表达hpv16 e5, e6, e7的肿瘤动物模型的构建
|
EP2666785A1
(en)
|
2012-05-23 |
2013-11-27 |
Affiris AG |
Complement component C5a-based vaccine
|
RU2659149C2
(ru)
|
2012-08-03 |
2018-06-28 |
Инфекшес Дизиз Рисерч Инститьют |
Композиции и способы для лечения активной инфекции mycobacterium tuberculosis
|
US20140037680A1
(en)
|
2012-08-06 |
2014-02-06 |
Glaxosmithkline Biologicals, S.A. |
Novel method
|
JP2015525794A
(ja)
|
2012-08-06 |
2015-09-07 |
グラクソスミスクライン バイオロジカルズ ソシエテ アノニム |
乳児においてrsv及び百日咳菌に対する免疫応答を惹起するための方法
|
US9605276B2
(en)
|
2012-08-24 |
2017-03-28 |
Etubics Corporation |
Replication defective adenovirus vector in vaccination
|
EP2703483A1
(en)
|
2012-08-29 |
2014-03-05 |
Affiris AG |
PCSK9 peptide vaccine
|
US9562066B2
(en)
*
|
2012-09-25 |
2017-02-07 |
University Of Pittsburgh-Of The Commonwealth System Of Higher Education |
Oral therapy of necrotizing enterocolitis
|
KR20220140025A
(ko)
|
2013-03-12 |
2022-10-17 |
더 트러스티스 오브 더 유니버시티 오브 펜실베니아 |
인간 파밀로마 바이러스용 개선된 백신 및 이것을 사용하는 방법
|
AR095425A1
(es)
|
2013-03-15 |
2015-10-14 |
Glaxosmithkline Biologicals Sa |
Vacuna, uso y procedimiento para prevenir una infección por picornavirus
|
EP2978447B1
(en)
|
2013-03-28 |
2019-05-08 |
Infectious Disease Research Institute |
Vaccines comprising leishmania polypeptides for the treatment and diagnosis of leishmaniasis
|
JP6564367B2
(ja)
|
2013-08-05 |
2019-08-21 |
グラクソスミスクライン バイオロジカルズ ソシエテ アノニム |
併用免疫原性組成物
|
EP2952893A1
(en)
|
2014-06-04 |
2015-12-09 |
Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) |
Method for detecting antibody-secreting B cells specific for HLA
|
BR112016028816A8
(pt)
|
2014-06-13 |
2021-07-20 |
Glaxosmithkline Biologicals Sa |
combinação imunogênica, método para obter uma resposta imunológica específica, uso de uma combinação imunogênica, e, regime de vacinação para prevenção, redução ou tratamento de infecção por vírus sincicial respiratório
|
AR102547A1
(es)
|
2014-11-07 |
2017-03-08 |
Takeda Vaccines Inc |
Vacunas contra la enfermedad de manos, pies y boca y métodos de fabricación y su uso
|
AR102548A1
(es)
|
2014-11-07 |
2017-03-08 |
Takeda Vaccines Inc |
Vacunas contra la enfermedad de manos, pies y boca y métodos de fabricación y uso
|
JP6738348B2
(ja)
|
2014-12-19 |
2020-08-12 |
リジェネサンス ベスローテン フェンノートシャップ |
ヒトc6に結合する抗体およびその使用
|
AU2016205215B2
(en)
|
2015-01-09 |
2021-03-11 |
Etubics Corporation |
Methods and compositions for combination immunotherapy
|
WO2016140702A1
(en)
|
2015-03-03 |
2016-09-09 |
The United States Of America, As Represented By The Secretary, Department Of Health & Human Serivces |
Display platform from bacterial spore coat proteins
|
US20180044429A1
(en)
|
2015-03-09 |
2018-02-15 |
Celldex Therapeutics, Inc. |
Cd27 agonists
|
US11149087B2
(en)
|
2015-04-20 |
2021-10-19 |
Etubics Corporation |
Methods and compositions for combination immunotherapy
|
CA2986961C
(en)
|
2015-05-26 |
2023-07-25 |
Ohio State Innovation Foundation |
Nanoparticle based vaccine strategy against swine influenza virus
|
CN106543272A
(zh)
*
|
2015-09-18 |
2017-03-29 |
江苏众红生物工程创药研究院有限公司 |
多功能标签融合蛋白及其表达方法和应用
|
CN109071665B
(zh)
|
2016-04-18 |
2022-11-01 |
塞德斯医疗公司 |
结合人cd40的激动性抗体及其用途
|
EP3458088A2
(en)
|
2016-05-21 |
2019-03-27 |
Infectious Disease Research Institute |
Compositions and methods for treating secondary tuberculosis and nontuberculous mycobacterium infections
|
MX2018014602A
(es)
|
2016-05-27 |
2019-06-10 |
Etubics Corp |
Composiciones de vacunas neoepitopos y metodos de uso de las mismas.
|
WO2018053294A1
(en)
|
2016-09-16 |
2018-03-22 |
Infectious Disease Research Institute |
Vaccines comprising mycobacterium leprae polypeptides for the prevention, treatment, and diagnosis of leprosy
|
CA3043790A1
(en)
|
2016-12-16 |
2018-06-21 |
Institute For Research In Biomedicine |
Novel recombinant prefusion rsv f proteins and uses thereof
|
WO2018162450A1
(en)
|
2017-03-06 |
2018-09-13 |
Fundación Para La Investigación Médica Aplicada |
New inmunostimulatory compositions comprising an entity of cold inducible rna-binding protein with an antigen for the activation of dendritic cells
|
SG11201909265QA
(en)
|
2017-04-19 |
2019-11-28 |
Inst Res Biomedicine |
Plasmodium sporozoite npdp peptides as vaccine and target novel malaria vaccines and antibodies binding to
|
US11141377B2
(en)
|
2017-06-15 |
2021-10-12 |
Infectious Disease Research Institute |
Nanostructured lipid carriers and stable emulsions and uses thereof
|
WO2019035963A1
(en)
|
2017-08-16 |
2019-02-21 |
Ohio State Innovation Foundation |
NANOPARTICLE COMPOSITIONS FOR VACCINES AGAINST SALMONELLA
|
CA3081578A1
(en)
|
2017-11-03 |
2019-05-09 |
Takeda Vaccines, Inc. |
Zika vaccines and immunogenic compositions, and methods of using the same
|
US20210046177A1
(en)
|
2018-01-26 |
2021-02-18 |
Nantcell, Inc. |
Compositions and methods for combination cancer vaccine and immunologic adjuvant therapy
|
JP7466459B2
(ja)
|
2018-04-17 |
2024-04-12 |
セルデックス セラピューティクス インコーポレイテッド |
抗cd27および抗pd-l1抗体ならびに二重特異性構築物
|
MX2021000548A
(es)
|
2018-07-19 |
2021-07-02 |
Glaxosmithkline Biologicals Sa |
Procesos para preparar polisacáridos en seco.
|
CN110004150B
(zh)
*
|
2018-08-01 |
2023-03-10 |
中国农业科学院兰州兽医研究所 |
一种具有免疫增强活性的CpG寡聚核苷酸序列及其应用
|
JP7320601B2
(ja)
|
2018-09-11 |
2023-08-03 |
上▲海▼市公共▲衛▼生▲臨▼床中心 |
広域スペクトルな抗インフルエンザワクチン免疫原及びその使用
|
CN109675028A
(zh)
*
|
2019-03-01 |
2019-04-26 |
龙阔(苏州)生物工程有限公司 |
疫苗佐剂及其制备方法和应用及猪繁殖与呼吸综合征疫苗
|
CN109985234A
(zh)
*
|
2019-04-12 |
2019-07-09 |
南华大学 |
一种梅毒螺旋体dna疫苗及其应用
|
WO2021146681A1
(en)
*
|
2020-01-17 |
2021-07-22 |
Inventprise, Llc |
Multivalent streptococcus vaccines
|
CN114075293B
(zh)
*
|
2020-08-14 |
2022-11-15 |
长沙诺盟生物医药有限公司 |
包含突变的hpv16 e6蛋白的融合蛋白和疫苗组合物
|
AU2021337493A1
(en)
|
2020-09-04 |
2023-05-18 |
Access To Advanced Health Institute |
Co-lyophilized rna and nanostructured lipid carrier
|
AU2022253269A1
(en)
|
2021-04-09 |
2023-11-23 |
Celldex Therapeutics, Inc. |
Antibodies against ilt4, bispecific anti-ilt4/pd-l1 antibody and uses thereof
|
WO2023077521A1
(en)
|
2021-11-08 |
2023-05-11 |
Celldex Therapeutics, Inc |
Anti-ilt4 and anti-pd-1 bispecific constructs
|
WO2023114727A1
(en)
|
2021-12-13 |
2023-06-22 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Bacteriophage lambda-vaccine system
|
WO2024052882A1
(en)
|
2022-09-09 |
2024-03-14 |
Access To Advanced Health Institute |
Immunogenic vaccine composition incorporating a saponin
|